These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Two Japanese families with familial pancreatic cancer with suspected pathogenic variants of CDKN2A: a case report. Kiyozumi Y; Matsubayashi H; Todaka A; Ashida R; Nishimura S; Kado N; Higashigawa S; Harada R; Ishihara E; Horiuchi Y; Honda G; Kenmotsu H; Serizawa M; Urakami K Hered Cancer Clin Pract; 2024 Jul; 22(1):11. PubMed ID: 38961426 [TBL] [Abstract][Full Text] [Related]
4. Uptake of genetic counseling, genetic testing and surveillance in hereditary malignant melanoma (CDKN2A) in Norway. Levin T; Mæhle L Fam Cancer; 2017 Apr; 16(2):257-265. PubMed ID: 27804060 [TBL] [Abstract][Full Text] [Related]
5. The Role of Inherited Pathogenic CDKN2A Variants in Susceptibility to Pancreatic Cancer. Kimura H; Klein AP; Hruban RH; Roberts NJ Pancreas; 2021 Sep; 50(8):1123-1130. PubMed ID: 34714275 [TBL] [Abstract][Full Text] [Related]
6. Clinical Significance of Germline Pathogenic Variants among 51 Cancer Predisposition Genes in an Unselected Cohort of Italian Pancreatic Cancer Patients. Puccini A; Ponzano M; Dalmasso B; Vanni I; Gandini A; Puglisi S; Borea R; Cremante M; Bruno W; Andreotti V; Allavena E; Martelli V; Catalano F; Grassi M; Iaia ML; Pirrone C; Pastorino A; Fornarini G; Sciallero S; Ghiorzo P; Pastorino L Cancers (Basel); 2022 Sep; 14(18):. PubMed ID: 36139606 [TBL] [Abstract][Full Text] [Related]
7. Psychosocial issues of individuals undergoing surveillance for increased risk of melanoma and pancreatic cancer due to a germline CDKN2A variant: A focus group study. Klatte DCF; Onnekink AM; Hinnen C; van Doorn R; Potjer TP; van Leerdam ME; Bleiker EMA J Genet Couns; 2023 Oct; ():. PubMed ID: 37876362 [TBL] [Abstract][Full Text] [Related]
13. Familial Melanoma: Diagnostic and Management Implications. Rossi M; Pellegrini C; Cardelli L; Ciciarelli V; Di Nardo L; Fargnoli MC Dermatol Pract Concept; 2019 Jan; 9(1):10-16. PubMed ID: 30775140 [TBL] [Abstract][Full Text] [Related]
14. Danishevich A; Bilyalov A; Nikolaev S; Khalikov N; Isaeva D; Levina Y; Makarova M; Nemtsova M; Chernevskiy D; Sagaydak O; Baranova E; Vorontsova M; Byakhova M; Semenova A; Galkin V; Khatkov I; Gadzhieva S; Bodunova N Biomedicines; 2023 Dec; 11(12):. PubMed ID: 38137564 [TBL] [Abstract][Full Text] [Related]
15. Increased prevalence of lung, breast, and pancreatic cancers in addition to melanoma risk in families bearing the cyclin-dependent kinase inhibitor 2A mutation: implications for genetic counseling. Potrony M; Puig-Butillé JA; Aguilera P; Badenas C; Carrera C; Malvehy J; Puig S J Am Acad Dermatol; 2014 Nov; 71(5):888-95. PubMed ID: 25064638 [TBL] [Abstract][Full Text] [Related]
16. Pancreatic Cancer Surveillance in Carriers of a Germline Klatte DCF; Boekestijn B; Wasser MNJM; Feshtali Shahbazi S; Ibrahim IS; Mieog JSD; Luelmo SAC; Morreau H; Potjer TP; Inderson A; Boonstra JJ; Dekker FW; Vasen HFA; van Hooft JE; Bonsing BA; van Leerdam ME J Clin Oncol; 2022 Oct; 40(28):3267-3277. PubMed ID: 35658523 [TBL] [Abstract][Full Text] [Related]
17. Predictors of germline status for hereditary melanoma: 5 years of multi-gene panel testing within the Italian Melanoma Intergroup. Bruno W; Dalmasso B; Barile M; Andreotti V; Elefanti L; Colombino M; Vanni I; Allavena E; Barbero F; Passoni E; Merelli B; Pellegrini S; Morgese F; Danesi R; Calò V; Bazan V; D'Elia AV; Molica C; Gensini F; Sala E; Uliana V; Soma PF; Genuardi M; Ballestrero A; Spagnolo F; Tanda E; Queirolo P; Mandalà M; Stanganelli I; Palmieri G; Menin C; ; Pastorino L; Ghiorzo P ESMO Open; 2022 Aug; 7(4):100525. PubMed ID: 35777164 [TBL] [Abstract][Full Text] [Related]
18. Pancreatic Cancer Surveillance in Carriers of a Germline Pathogenic Variant in Llach J; Aguilera P; Sánchez A; Ginès A; Fernández-Esparrach G; Soy G; Sendino O; Vaquero E; Carballal S; Ausania F; Ayuso JR; Darnell A; Pellisé M; Castellví-Bel S; Puig S; Balaguer F; Moreira L Cancers (Basel); 2023 Mar; 15(6):. PubMed ID: 36980574 [TBL] [Abstract][Full Text] [Related]
19. FRAMe: Familial Risk Assessment of Melanoma-a risk prediction tool to guide CDKN2A germline mutation testing in Australian familial melanoma. Holland EA; Lo S; Kelly B; Schmid H; Cust AE; Palmer JM; Drummond M; Hayward NK; Pritchard AL; Mann GJ Fam Cancer; 2021 Jul; 20(3):231-239. PubMed ID: 32989607 [TBL] [Abstract][Full Text] [Related]
20. Indication for CDKN2A-mutation analysis in familial pancreatic cancer families without melanomas. Harinck F; Kluijt I; van der Stoep N; Oldenburg RA; Wagner A; Aalfs CM; Sijmons RH; Poley JW; Kuipers EJ; Fockens P; van Os TA; Bruno MJ J Med Genet; 2012 Jun; 49(6):362-5. PubMed ID: 22636603 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]